Payment overview · 2025
General Payments
$679.93
24 reported records · 13 companies
Healthcare provider profile · identity verified
Patrick Friedli, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TRAVERSE CITY, MI · NPI 1255341046
Verified facts
What the public records show
CMS Open Payments records show Patrick Friedli, M.D. received $679.93 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Paxlovid, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.59 | 25.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $156.46 | 23.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.45 | 13.3% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $42.42 | 6.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.51 | 6.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $32.03 | 4.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.03 | 4.4% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $28.05 | 4.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.94 | 3.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.72 | 2.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.86 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.12 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.75 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $679.93 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $146.52 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $134.06 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.64 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $42.42 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $28.05 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 87 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 87 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 119 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
119 | 27 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
87 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 475 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 459 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 324 | 102 |
| Lisinopril | Lisinopril | 315 | 91 |
| Alprazolam | Alprazolam | 280 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 76 |
| Omeprazole | Omeprazole | 253 | 77 |
| Simvastatin | Simvastatin | 204 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 55 |
| Gabapentin | Gabapentin | 167 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 41 |
| Losartan Potassium | Losartan Potassium | 155 | 48 |
| Metformin Hcl | Metformin Hcl | 138 | 38 |
| Allopurinol | Allopurinol | 131 | 35 |
| Lorazepam | Lorazepam | 124 | 23 |
| Prednisone | Prednisone | 121 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 119 | 27 |
| Sertraline Hcl | Sertraline Hcl | 112 | 38 |
| Meloxicam | Meloxicam | 105 | 41 |
| Tramadol Hcl | Tramadol Hcl | 103 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 30 |
| Furosemide | Furosemide | 92 | 31 |
| Trazodone Hcl | Trazodone Hcl | 91 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 25 |
| Eliquis | Apixaban | 87 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 27 |
| Mounjaro | Tirzepatide | 87 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 22 |
| Bupropion Xl | Bupropion Hcl | 84 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 25 |
| Methylprednisolone | Methylprednisolone | 77 | 59 |
| Farxiga | Dapagliflozin Propanediol | 74 | 24 |
| Jardiance | Empagliflozin | 74 | 18 |
| Donepezil Hcl | Donepezil Hcl | 73 | 18 |
| Atenolol | Atenolol | 68 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 19 |
| Azithromycin | Azithromycin | 67 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 20 |
| Trulicity | Dulaglutide | 63 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 56 | 31 |
| Famotidine | Famotidine | 54 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 35 |
| Valsartan | Valsartan | 54 | 16 |
| Ibuprofen | Ibuprofen | 50 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 22 |
| Spironolactone | Spironolactone | 48 | 17 |
| Levofloxacin | Levofloxacin | 46 | 39 |
| Metformin Hcl Er | Metformin Hcl | 46 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 13 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Estradiol | Estradiol | 44 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 44 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 15 |
| Potassium Chloride | Potassium Chloride | 44 | 12 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Clonazepam | Clonazepam | 42 | 15 |
| Carvedilol | Carvedilol | 41 | 12 |
| Ezetimibe | Ezetimibe | 41 | 15 |
| Myrbetriq | Mirabegron | 41 | 15 |
| Montelukast Sodium | Montelukast Sodium | 39 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 12 |
| Mirtazapine | Mirtazapine | 35 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 21 |
| Finasteride | Finasteride | 34 | suppressed |
| Nystatin | Nystatin | 34 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 27 |
| Topiramate | Topiramate | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | 11 |
| Fluconazole | Fluconazole | 31 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 30 | 12 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 20 |
| Diazepam | Diazepam | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 16 |
| Acyclovir | Acyclovir | 21 | 11 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 15 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Pregabalin | Pregabalin | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $679.93 · 24 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, JARDIANCE, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, PAXLOVID, QULIPTA, REPATHA, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error